Valuation : AbbVie Inc.

Market Cap 443B 14,652B 381B 360B 328B 613B 42,391B 618B 4,285B 1,649B 21,502B 1,665B 1,629B 68,295B P/E 2026 *
32.1x
P/E 2027 * 23.9x
Enterprise Value 504B 16,651B 433B 409B 372B 696B 48,175B 703B 4,869B 1,874B 24,435B 1,892B 1,851B 77,612B EV / Sales 2026 *
7.46x
EV / Sales 2027 * 6.73x
Free-Float
95.71%
Yield 2026 *
2.73%
Yield 2027 * 2.87%
03:37pm AbbVie Announces Positive Phase 3 Atogepant Results in Menstrual Migraine CI
02:54pm AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial DJ
02:41pm AbbVie's menstrual migraine treatment meets late-stage study goal RE
02:31pm AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study MT
02:03pm AbbVie's migraine treatment meets late-stage study goal RE
11:14am HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating MT
09-09 AbbVie Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
09-08 BofA Securities Adjusts Price Target on AbbVie to $282 From $276 MT
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
1 week-4.05%
Current month-1.78%
1 month+1.84%
3 months+13.70%
6 months+12.93%
Current year+13.70%
1 week 8.15
Extreme 8.15
8.65
1 month 8.1
Extreme 8.1
8.8
Current year 6.25
Extreme 6.25
8.85
1 year 6.25
Extreme 6.25
8.85
3 years 6.25
Extreme 6.25
8.85
5 years 6.25
Extreme 6.25
8.85
10 years 6.25
Extreme 6.25
8.85
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 69 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.05% - - 443B
+0.29%-2.80%+49.36%+89.25% 1,002B
-0.12%-4.23%+51.69%+63.94% 644B
+0.58%-2.94%+19.34%+69.46% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.33%-13.86%+37.36%+46.17% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.34%-4.20%+25.70%+88.05% 181B
Average -0.05%-5.00%+22.76%+41.53% 392.19B
Weighted average by Cap. +0.06%-4.24%+32.03%+56.06%

Financials

2026 *2027 *
Net sales 67.58B 2,233B 58.12B 54.84B 49.96B 93.39B 6,462B 94.24B 653B 251B 3,277B 254B 248B 10,410B 73.52B 2,430B 63.23B 59.66B 54.35B 102B 7,029B 103B 710B 273B 3,565B 276B 270B 11,324B
Net income 13.86B 458B 11.92B 11.25B 10.25B 19.15B 1,325B 19.33B 134B 51.56B 672B 52.05B 50.92B 2,135B 18.91B 625B 16.27B 15.35B 13.98B 26.14B 1,808B 26.37B 183B 70.35B 917B 71.03B 69.47B 2,913B
Net Debt 60.49B 1,999B 52.02B 49.08B 44.72B 83.59B 5,783B 84.35B 585B 225B 2,933B 227B 222B 9,317B 51.66B 1,707B 44.43B 41.92B 38.19B 71.39B 4,939B 72.04B 499B 192B 2,505B 194B 190B 7,957B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
09/09/26 THB 8.300 0.00% 4,613
09/09/26 THB 8.300 -1.19% 292,399
08/09/26 THB 8.400 -1.18% 4,046
07/09/26 THB 8.500 -0.58% 97,801
04/09/26 THB 8.550 -1.72% 47,191
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
250.91USD
Average target price
277.31USD
Spread / Average Target
+10.52%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!